Literature DB >> 17223503

Hepatocellular carcinoma development in cirrhosis.

Hiroaki Okuda1.   

Abstract

The development of hepatocellular carcinoma (HCC), the mechanisms of hepatocarcinogenesis, the prevention of HCC, and screening for HCC will be discussed. Cirrhosis has been considered as a pre-neoplastic condition for the development of HCC. The worldwide incidence of HCC differs according to different hepatitis viruses, and information is lacking. Hepatocarcinogenesis is a multistep process involving a number of different genetic alterations and is poorly understood. Interferon should help prevent the development of HCC in patients with chronic hepatitis C. Screening is the only practical approach for improving the management of HCC patients, as early detection increases the application of curative treatments. However, the cost-effectiveness of various screening strategies needs to be analysed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223503     DOI: 10.1016/j.bpg.2006.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  24 in total

1.  Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.

Authors:  Sadahisa Ogasawara; Fumihiko Kanai; Shuntaro Obi; Shinpei Sato; Taketo Yamaguchi; Ryosaku Azemoto; Hideaki Mizumoto; Youhei Koushima; Naoki Morimoto; Nobuto Hirata; Takeshi Toriyabe; Yusuke Shinozaki; Yoshihiko Ooka; Rintaro Mikata; Tetsuhiro Chiba; Shinichiro Okabe; Fumio Imazeki; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2011-01-22       Impact factor: 6.047

2.  A novel curcumin analogue is a potent chemotherapy candidate for human hepatocellular carcinoma.

Authors:  Ji-An Zhao; Mei-Xiang Sang; Cui-Zhi Geng; Shi-Jie Wang; Bao-En Shan
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

3.  Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma.

Authors:  Jian-zhong Di; Xiao-dong Han; Wen-ye Gu; Yu Wang; Qi Zheng; Pin Zhang; Hui-min Wu; Zhong-zheng Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2011-10       Impact factor: 3.066

4.  MicroRNA301 is a potential diagnostic biomarker for hepatocellular cancer.

Authors:  Kun He; Zemin Hu; Jiahou Ruan; Qianhong Ma; Feng Zhong; Xinsheng Cheng; Shibo Sun; Jie Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Curcumin ameliorate DENA-induced HCC via modulating TGF-β, AKT, and caspase-3 expression in experimental rat model.

Authors:  Mekky M M Abouzied; Heba M Eltahir; Mohamed A Abdel Aziz; Nagwa S Ahmed; Ahmed A Abd El-Ghany; Ebtihal A Abd El-Aziz; Hekmat O Abd El-Aziz
Journal:  Tumour Biol       Date:  2014-12-18

6.  [Oncologic imaging: indications for and limitations of modern cross-sectional imaging techniques].

Authors:  M E Mayerhoefer; A Ba-Ssalamah; H Prosch
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

Review 7.  Natural history of hepatitis-related hepatocellular carcinoma.

Authors:  David-Yiu-Kuen But; Ching-Lung Lai; Man-Fung Yuen
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

8.  Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

Authors:  Jinmai Jiang; Yuriy Gusev; Ileana Aderca; Teresa A Mettler; David M Nagorney; Daniel J Brackett; Lewis R Roberts; Thomas D Schmittgen
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

9.  Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.

Authors:  Jennifer Altomonte; Sabrina Marozin; Enrico N De Toni; Antonia Rizzani; Irene Esposito; Katja Steiger; Annette Feuchtinger; Claus Hellerbrand; Roland M Schmid; Oliver Ebert
Journal:  Mol Ther       Date:  2013-08-13       Impact factor: 11.454

10.  Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis.

Authors:  Wenjun Cao; Bill Sun; Mark A Feitelson; Tong Wu; Ran Tur-Kaspa; Qishi Fan
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.